Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma
KURA•Cash position and planned development updates
Cash and investments totaled $580.8 million as of 3/31/26; management also cited $180 million in anticipated payments.
Phase 1b expansion is enrolling cabozantinib-naive clear-cell RCC; a Phase 1a escalation with daraxonrasib in second-line or later PDAC is planned.
Investor presentation highlights FIT-001 renal cell carcinoma data
Kura Oncology highlighted Phase 1a FIT-001 data for darlifarnib with cabozantinib in advanced RCC, supporting continued combination development.
Cabozantinib-naive clear-cell RCC showed ORR of 33%-50% across dose cohorts; median PFS was 13 months.
Across 72 treated RCC patients, grade ≥3 treatment-emergent adverse events occurred in 76%; neutropenia was 38%.
